Annual report pursuant to Section 13 and 15(d)

DEVELOPMENT AWARDS AND DEFERRED REVENUE (Details Narrative)

v3.22.4
DEVELOPMENT AWARDS AND DEFERRED REVENUE (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Jul. 31, 2020
Jan. 26, 2018
May 31, 2019
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Entity Listings [Line Items]                
Revenue       $ 0 $ 881,705      
CFF Warrant [Member]                
Entity Listings [Line Items]                
Warrant exercisable price per share       $ 396        
Cystic Fibrosis Program Related Investment Agreement [Member] | Phase 2b Clinical Trial [Member]                
Entity Listings [Line Items]                
Accrued Royalties, Current     $ 2,700,000          
Payments for Royalties     $ 27,000,000          
Proceeds from investments on achieving milestones       $ 25,000,000        
Cystic Fibrosis Program Related Investment Agreement [Member] | Maximum [Member]                
Entity Listings [Line Items]                
Gain Contingency, Unrecorded Amount   $ 25,000,000            
Investment Agreement [Member] | 2018 CFF Award [Member]                
Entity Listings [Line Items]                
Revenue       $ 0 881,705      
Investment Agreement [Member] | CFF Warrant [Member]                
Entity Listings [Line Items]                
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right       33,333        
Warrants and Rights Outstanding, Maturity Date       Jan. 26, 2025        
Investment Agreement [Member] | CFF Warrant [Member] | Immediately Exercisable Warrants [Member]                
Entity Listings [Line Items]                
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right       16,667        
Investment Agreements [Member]                
Entity Listings [Line Items]                
Revenue $ 25,000,000       $ 2,500,000 $ 5,000,000 $ 5,000,000 $ 12,500,000
Investment Agreements [Member] | CFF Warrant [Member] | Warrants Exercisable On Completion Of Final Milestone [Member]                
Entity Listings [Line Items]                
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right       16,667        
Investment Agreements [Member] | Cystic Fibrosis Foundation Warrants [Member]                
Entity Listings [Line Items]                
Revenue       $ 25,000,000        
Adjustments to Additional Paid in Capital, Warrant Issued       6,215,225        
Revenue to be recognized       18,784,775        
Investment Agreements [Member] | Cystic Fibrosis Foundation [Member] | CFF Warrant [Member]                
Entity Listings [Line Items]                
Adjustments to Additional Paid in Capital, Warrant Issued       $ 6,215,225        
Collaboration Agreement [Member] | Cystic Fibrosis Foundation [Member]                
Entity Listings [Line Items]                
Royalty payment percentage   10.00%